OLMA Olema Pharmaceuticals Inc.

FDA Catalyst Company
2.39
+0.13  (+6%)
Previous Close 2.26
Open 2.32
52 Week Low 2
52 Week High 32.77
Market Cap $96,443,194
Shares 40,352,801
Float 26,257,414
Enterprise Value $-173,628,670
Volume 551,513
Av. Daily Volume 380,222
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/28/2022
Canaccord Genuity Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/14/2020

Latest News

    • Phase 1/2 trial of OP-1250 continues to enroll patients in the dose expansion stage, with selection of Recommended Phase 2 Dose expected in Q2 2022
    • Phase 1b combination study with palbociclib ongoing; Additional combination trials with CDK4/6 and PI3Kα inhibitors planned to initiate in 2H 2022
    • Company expects to present updated monotherapy and initial combination data in 2022
    • Strong cash, cash equivalents, and marketable securities of $267.9 million as of March 31, 2022, sufficient to fund operations into 2024

    SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted…

    View Full Article
  1. SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 14, 2022, at 11:30 a.m. ET (8:30 a.m. PT).

    A live webcast of the presentation may be accessed under the Investors & Media section of Olema's website (www.olema.com) and will be archived for 14 days. 

    About Olema Oncology 
    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate…

    View Full Article
  2. SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced plans to present two posters related to nonclinical data for OP-1250, a potent, oral complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 8-13, 2022.

    Details of the poster presentations are as follows:

    Title: Precision run-on sequencing (PRO-seq) analysis of a treatment time course in ER+ breast cancer cell lines reveals…

    View Full Article
    • Presented Phase 1a proof-of-concept data for OP-1250 in metastatic, ER+ / HER2- breast cancer, with demonstrated attractive pharmacokinetics, favorable tolerability and encouraging anti-tumor activity in a heavily pretreated patient population
    • Enrollment in Phase 1b dose expansion on track to complete in Q1 2022; Phase 2 to initiate in H1 2022
    • Initiated Phase 1b combination study with palbociclib; Additional combination trials with CDK4/6 and PI3Kα inhibitors planned in 2022
    • Appointed biotech industry veteran Naseem Zojwalla, M.D., as Chief Medical Officer
    • Strong cash, cash equivalents and marketable securities position of $287.3 million as of December 31, 2021 sufficient to fund operations into 2024

    SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE…

    View Full Article
  3. SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 2:50 p.m. ET (11:50 a.m. PT).

    A live webcast of the presentation may be accessed under the Investors & Media section of Olema's website (www.olema.com) and will be archived for 14 days. 

    About Olema Oncology 
    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is…

    View Full Article
View All Olema Pharmaceuticals Inc. News